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antiandrogen cortexolone-17a-propionate and
related compounds through theoretical
calculations and nuclear magnetic resonance
spectroscopy
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Laura Ragonesic and Diego Colombo*a
Cortexolone-17a-propionate is a topical antiandrogen under investigation for the treatment of androgen-
related skin disorders. A full conformational characterization was realized, in comparison with other
steroidal androgens and antiandrogens, by means of theoretical calculations at the B3LYP/6-31G(d) level
supported by high-ﬁeld NMR analyses. All of the studied molecules showed a good overlay;
nevertheless, the diﬀerent functional groups present in the skeleton of the molecules drive the individual
biological proﬁle.Introduction
The skin's capability of synthesizing and converting androgens
is well documented.1 The 5a-reductase-catalyzed trans-
formation of testosterone 1 aﬀords dihydrotestosterone (DHT,pounds.
Medicina Traslazionale, Universita` di
y. E-mail: diego.colombo@unimi.it; Fax:
Studi di Pavia, Via Taramelli 12, 27100
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904–9142) (Fig. 1), the most active metabolite involved in many
androgen-related skin disorders such as hirsutism, androgen
alopecia and acne.1–5 The treatment of these disorders can be
realized by either inhibiting the 5a-reductase or antagonizing
the binding of testosterone and DHT at the androgen binding
sites.6 Known androgen antagonists, such as nasteride 6 or
cyproterone acetate 7, when systemically administered, show
benecial eﬀects in the management of these skin disorders
together with an interference with the hormonal environment
in male and female patients.7 Several years ago we investigated8
the antiandrogenic activity of a family of 17a-esters of cortex-
olone (17a,21-dihydroxy-4-pregnene-3,20-dione 3), an interme-
diate of the glucocorticoid biosynthesis, devoid of endocrine
function, with the exception of a weak glucocorticoid activity.9
Among the studied esters, 17a-propionate 4 showed a strong
local antiandrogenic activity in the hamster ank organ test10
being, on the contrary, ineﬀective when subcutaneously injec-
ted by repeated administrations in animals even at very high
doses.8 The systemic antiandrogenic activity of 17a-propionate
of cortexolone was assessed by its ability to decrease the weight
of the androgen-dependent organs (ventral prostate, seminal
vesicles and preputial glands) stimulated by the injection of
testosterone propionate (TP).8
The absence of systemic antiandrogenic eﬀects could be
explained considering that the propionate, aer percutaneous
application, is quickly hydrolyzed by the skin and plasma
esterases into the inactive parent cortexolone (3) getting
through the 21-propionate 5.
The topical activity of compound 4 is higher than that of
nasteride 6 and about equivalent to that of cyproterone
acetate 7.This journal is © The Royal Society of Chemistry 2014
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View Article OnlineTaking into account the topical activity of propionate 4
coupled with the lack of systemic activity, we planned to
compare this 17a-ester with the well-known antiandrogen
cyproterone acetate 7 and with the natural androgens, testos-
terone 1 and dihydrotestosterone 2, from a conformational
point of view.
In fact, the conformation of a biologically active compound
plays a central role when it interacts with the target, for
example, a receptor or an enzyme; among the possible confor-
mations only one could be able to stimulate the biological
response as we also reported in a previous work.11 The choice of
the compounds to be compared with propionate 4 was driven by
its antiandrogenic activity. In fact testosterone (1) and dihy-
drotestosterone (2) are antagonized both by compounds 4 and 7
with the same action mechanism that does not implicate the
interference with the 5a-reductase. The conformational char-
acterization was realized by means of theoretical calculations,
validated by complete assignment of the 1H and 13C NMR
signals, as in the case of our previous studies of steroidal
compounds.11Fig. 2 [14C]-testosterone (T, 1) metabolism and DHT (2) production in
presence of cortexolone-17a-propionate (4) or ﬁnasteride (6).Results and discussion
Biological activity of cortexolone-17a-propionate (4)
Local activity and mechanism of action of cortexolone-17a-
propionate (4). The local activity of 4 was established by means
of the hamster ank organ test.8 The results are summarized in
Table 1 (for a more exhaustive discussion see ref. 8). The anti-
androgenic activity of 4 is dose-related; the parent cortexolone
(3) is devoid of eﬀect; when compared to other androgen
antagonists, administered at a xed dose (400 mg), compound 4
resulted in being two times more active than nasteride (6) and
about as active as cyproterone acetate (7).
As concerns the mechanism of action, compound 4,
compared to nasteride (6) the well-known inhibitor of 5a-
reductase, did not inhibit the conversion of testosterone (1) to
DHT (2) in reconstructed human epidermis (Cosmo R & D
personal communication), thus resulting in the absence of
inhibitory activity on the 5a-reductase, as shown by the studied
[14C]-testosterone metabolism aer 24 h transepidermal diﬀu-
sion (Fig. 2).
Additional experiments (Cosmo R & D personal communi-
cation) showed that in the binding aﬃnity test to the androgen-Table 1 Local antiandrogenic activity in hamster ﬂank organa
Topical treatment (acetone 0.05 mL) Da
Cortexolone (3) + TP 40
Finasteride (6) + TP 40
Cyproterone acetate (7) + TP 40
Cortexolone-17a-propionate (4) + TP 10
Cortexolone-17a-propionate (4) + TP 20
Cortexolone-17a-propionate (4) + TP 40
a The local antiandrogenic activity of 4 and other tested compounds 3, 6
enlargement induced by the topical application of testosterone propiona
**P < 0.01.
This journal is © The Royal Society of Chemistry 2014receptor of human prostate cancer cells, compound 4 inhibited
the specic binding of [3H] methyltrienolone (R1881) to the
androgen receptor with a Ki value of 4.0  108, and an IC50
value of 5.0  108 M. As a consequence, compound 4 should
be considered as an antiandrogen acting at the androgen-
receptor level.
Systemic activity of cortexolone-17a-propionate (4). Systemic
antiandrogenic activity of 4 was evaluated in male castrated rats
primed with TP. Aer repeated subcutaneous injections of 0.2–1
and 5 mg per animal, compound 4 was completely unable to
antagonize the stimulating eﬀect of TP on the target organs
ventral prostate, seminal vesicles, and preputial glands.8 Also,
parent cortexolone (3) resulted in being devoid of activity in this
test.8 Compound 4 was also endowed with glucocorticoid
activity (adrenals and thymus weight inhibition), detectable
only at the highest tested dose equivalent to about 100 mg per
kg of body weight. Considering the very high dose required to
obtain the glucocorticoid activity, this eﬀect should be minimal
and of little importance when the product is administered by
topical route.8 In addition, in the antigonadotropic activity test
17a-propionate 4, even injected at the highest dose, was
completely devoid of activity on gonadotropin hypersecretion,
as compared to progesterone. These data demonstrate that
compound 4 is a peripherally selective antiandrogen not
aﬀecting the CNS.8
Metabolism of cortexolone-17a-propionate (4). The absence
of systemic activity can be explained by a rapid hydrolysis of the
17a-ester aﬀording the inactive cortexolone (3). Cortexolone-
17a-propionate (4), when incubated in rat plasma, was rapidly
converted (50%) to free cortexolone (3) within 2 h of incubation
and completely metabolized within 8 h (Table 2). The acyl groupily doseb Flank organ inhibitionc (%)
0 + 4 0
0 + 4 71*
0 + 4 93**
0 + 4 40*
0 + 4 78*
0 + 4 84**
, and 7 was expressed as the percentage inhibition of the ank organ
te (TP) alone. b mg per animal, antiandrogen + androgen. c *P < 0.05,
Med. Chem. Commun., 2014, 5, 904–914 | 905
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View Article Onlineinitially undergoes a non-enzymatic migration to the 21-posi-
tion and subsequently an esterase-catalyzed hydrolysis aﬀord-
ing the inactive cortexolone (3). The formation of intermediate 5
was investigated by incubating 4 at 37.8 C for up to 8 h in the
absence or presence of 50 mg mL1 of enzymatic inhibitor
dichlorvos. When the incubation was performed in the presence
of the inhibitor, a large amount of cortexolone-21-propionate (5)
was detected, thus conrming that the biotransformation of
17a-propionate 4 to cortexolone (3) takes place by the produc-
tion of 21-propionate 5, as an eﬀect of non-enzymatic migration
of the propionyl group from the 17a-position to the 21-position,
and subsequent hydrolysis of the 21-propionate (5) to cortex-
olone (3).
An analogous metabolic prole of 4 was observed with
incubation in human plasma (Table 3).
In rat skin homogenate the metabolic transformation of 4 to
cortexolone (3) reached a peak (40–44.7%) within 8–16 h, and
remained stable during the remnant incubation period of up to
24 h (Table 4).
Biological activity of cortexolone-21-propionate (5) and cor-
texolone-17a,21-dipropionate (8). In Table 5 is reported the
local antiandrogenic activity of compounds 5 and 8, showing in
the ability of the tested steroids (400 mg) to inhibit the
enlargement of the hamster ank organ test, in turn produced
by the administration of TP (4 mg). The 21-monoesterication of
cortexolone (3) leads to compound 5 being nearly devoid of
activity, like the parent cortexolone (3). The 17a,21-die-
sterication (compound 8) reduces the antiandrogenic activity
granted by the 17a-esterication of compound 4 (84% inhibi-
tion, Table 1).
Biological activity of 9,11-dehydrocortexolone-17a-butyrate
(9). The 9,11-dehydrocortexolone-17a-butyrate (9), based on the
results of the screening phase, was identied as the most potent
topical antiandrogen among the 17a-monoesters; in fact, it
showed an 85% ability to inhibit the enlargement of the ham-
ster's ank organ produced by topical administration of TP
(Table 5), whereas the corresponding saturated 17a-butyrate
showed a 76% ability.
Diﬀerently from the 17a-monoesters of cortexolone, 9,11-
dehydrocortexolone-17a-butyrate (9) was found to show
systemic activity in the rat aer subcutaneous injection.12
Compound 9 was also discovered to be a potent inhibitor of
gonadotropin hypersecretion, thus mimicking the activity
prole of cyproterone acetate (7), which blocks the androgen-Table 2 Metabolism of 4 in rat plasma
Incubation
time
Cortexolone-17a-propionate
(4) (%)
Cortexolone
(3) (%)
0 100 0
5 min 95–90 5–10
15 min 95–90 5–10
30 min 90–80 10–20
1 h 80–60 20–40
2 h 50 50
4 h 40–20 60–80
8 h 10–0 90–100
906 | Med. Chem. Commun., 2014, 5, 904–914receptor interaction and simultaneously reduces serum testos-
terone through its antigonadotropic action.13,14 The presence of
a double bond at position 9,11 of the cortexolone, modifying the
spatial conformation of the steroids rings, could be responsible
for the systemic and increased topical activity of 9.12Conformational properties
The above observations prompted us to study the conforma-
tional properties of compound 4 and of the related compounds
to establish and compare their preferred conformations. To this
end, other known androgenic or antiandrogenic steroids were
simultaneously analyzed including testosterone (1) and its most
potent metabolite DHT (2) active in the skin, cortexolone (3) and
its derivatives 8 and 9 and cyproterone acetate (7).
Conformational properties of compounds 1 and 2. An
extensive exploration of the conformational space of
compounds 1 and 2 was carried out through DFT calculations at
the B3LYP/6-31G(d) level. Attention was focused on the tetra-
cyclic system and on the possibility of inversion of the hex-
acyclic rings. Compound 1 prefers conformation 1A in which
ring A assumed a half-chair geometry due to the presence of the
double bond between C4 and C5. Conformation 1Ab diﬀers
from 1A (Fig. 3) only in the orientation of the hydroxyl group at
C17 and it is less stable by 0.27 kcal mol1. These two geome-
tries account for more than 97% of the overall population
(Table 6). The inversion of ring A (1B) resulted in a geometry less
stable by about 2 kcal mol1, whereas inversion of rings B and C
gave two geometries (1C, 1D) less stable by 6.05 and 11.13
kcal mol1, respectively (Table 6). Concerning compound 2, the
preferred conformation A showed the expected chair geometry
of the hexacyclic rings and a twisted geometry of ring D. The
inversion of ring A is easier than the others, but the corre-
sponding conformation (2B) is less stable by more than 3
kcal mol1, leaving 2A and the analogous 2Ab conformation the
only ones signicantly populated; in fact, they account for more
than 99% of the overall population. These two geometries diﬀer
only in the orientation of the hydroxyl group at C17 that has two
accessible orientations with a small diﬀerence in energy (0.31
kcal mol1). The preferred one is that with s1z 170 (2A) (Fig. 3
and Table 6).
Some short contacts characterize the conformational pref-
erences of the rings of 2: H-2ax/CH3-10 (2.81 A˚), and H-4ax/CH3-
10 (2.76 A˚) for the A ring; H-6ax/CH3-10 (2.72 A˚), H-8ax/CH3-10
(2.86 A˚) for the B-ring conformation; H-11ax/CH3-10 (2.73 A˚),
H-11ax/CH3-13 (2.76 A˚), and H-8ax/CH3-13 (2.78 A˚) for the
C ring; H-15ax/CH3-13 (2.90 A˚) for ring D.
Conformational properties of compounds 3, 4 and 7–9. The
conformational space of compounds 3, 4, 7, 8 and 9 was
analyzed at the same level as above. Analogously to 1, ring A
presents, in all cases, an unsaturation between C4 and C5 that
forces it to assume a half-chair geometry. In Table 6 the most
representative conformations are reported. The preferred
conformation of compounds 3, 4, 7, 8 and 9 (Fig. 4 and 5),
located in the present study, corresponds, in the tetracyclic
skeleton, to the geometry already determined at the same level
of calculations for progesterone and a group of 13-ethylsteroidsThis journal is © The Royal Society of Chemistry 2014
Table 3 Metabolism of 4 in human plasma
Incubation time Cortexolone-17a-propionate (4) (%) Cortexolone-21-propionate (5) (%) Cortexolone (3) (%)
0 99.6 0.5 0.0
30 min 93.2 6.5 0.4
1 h 85.2 13.2 1.7
2 h 67.2 25.3 7.5
4 h 30.3 33.8 35.9
6 h 11.3 23.8 64.9
Concise Article MedChemComm
Pu
bl
ish
ed
 o
n 
04
 A
pr
il 
20
14
. D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ita
 S
tu
di
 d
i M
ila
no
 o
n 
26
/1
1/
20
14
 1
5:
54
:1
4.
 
View Article Onlineand related estrogens modeled in previous papers.11 In fact, as
can be seen from Table 6, they show very close values of
torsional angles (sA–C) and puckering coordinates.
The energy proles for rotation around the C17–C20, and
C17–O single bonds, dened by s1 and s2, were obtained and the
preferred orientations determined. The C17–C20 bond showed
a quite balanced distribution of its possible orientations, with
the presence, for all compounds, of two signicantly populated
geometries that present s1 z 160, and s1 z 10, respectively.
For 3 and 8 conformation Ab, with s1z10, is favoured by 0.63
and 1.29 kcal mol1, respectively, whereas 4 and 9 prefer the
other orientation by 0.46 and 0.25 kcal mol1, respectively.
Concerning the C17–O bond, in the case of 4, 8, and 9, a
signicant preference was observed for the orientation charac-
terized by s2 z 60, with the other higher in energy by 4–6
kcal mol1, whereas in 3 the hydroxyl group bonded at C17
shows two orientations related to the value of s1, being
preferred s2 ¼ 45 for s1 ¼ 146, and s2 ¼ 159 for s1 ¼ 24. In
compound 8, the hydroxyl at C21, present in 3, 4, and 9, is
esteried, with the generation of a second propionate group.
Considering the oxoethyl propionate bonded at C17 the
torsional angle s3 describes the relative orientation of the two
carbonyl groups of the chain. The second one is perpendicular
to the rst (s3 z 90), whatever the orientation of this latter
(see s1).
A careful analysis of the conformational freedom of the tet-
racyclic skeleton allowed us to determine the facility of inver-
sion of the three hexacyclic rings. The A ring inversion from the
1a,2b-half-chair to the 1b,2a-half-chair conformation (3, 4, 8, 9A
/ 3, 4, 8, 9B) is the easiest among all the possible ring inver-
sions. In the case of compounds 3, 4, and 8, the A ring inversionTable 4 Metabolism of 4 in rat skin homogenate
Incubation time Cortexolone-17a-propionate (4) (%)
0 99
5 min 99
15 min 99
30 min 98.5
1 h 89.5
2 h 69.5
4 h 59.5
8 h 49.5
16 h 44.75
24 h 44.75
This journal is © The Royal Society of Chemistry 2014brings about a conformation less stable by about 2 kcal mol1.
For compound 9 the same inversion is easier, giving the
conformation 9B with an energy value of 1.34 kcal mol1. So the
percentage contribution of the 1b,2a-half-chair conformation to
the overall population is double in the case of 9 with respect to
the others, although the 1a,2b-half-chair conformation remains
widely preferred.
As regards B ring inversion, the obtained conformations C,
presenting a relative energy of about 4–6 kcal mol1, respec-
tively, do not give any contribution to the overall population.
The ring C inversion of 9 is not possible because of the presence
of the double bond, whereas for 3, 4 and 8 a conformation (D) is
obtained that is higher in energy than the global minimum by
more than 10 kcal mol1.
In 3, 4, 8 and 9 the preference of ring A for the 1a,2b-half-
chair conformation is characterized by the short contact H-2ax/
CH3-19 (2.90 A˚). The contacts H-6ax/CH3-19 (2.91 A˚), and H-8ax/
CH3-19 (2.87 A˚) conrm the B ring conformation; contacts
H-8ax/CH3-18 (2.74 A˚), H-11ax/CH3-19 (2.70 A˚), and H-11ax/CH3-
18 (2.73 A˚) assure the C ring geometry, whereas contact H-15ax/
CH3-18 (2.90 A˚) gives the D ring conformation.
Finally, the diﬀerent orientations of s1 could be veried
through contacts H-21b/H-12eq (2.48, 2.29, 2.36 A˚, respectively,
for 3, 4, and 8) for conformation A; H-21a,b/CH3-18 (2.63, 2.82,
2.90 A˚), H-21a/H-16 (2.42, 2.25, 2.27 A˚), and H-21b/H-16
(2.37, 2.43, 2.46 A˚) for conformation Ab.
Analogously, conformation A of compound 9 presents the
contacts: H-2ax/CH3-19 (2.85 A˚) for ring A; H-6ax/CH3-19 (2.94 A˚)
for ring B; H-21a/H-12eq (2.39 A˚) for s1 ¼ 156. The second
orientation of s1 could be veried through contacts: H-21b/CH3-
18 (2.88 A˚), H-21b/H-16 (2.24 A˚), and H-21a/H-16 (2.48 A˚).Cortexolone-21-propionate (5) (%) Cortexolone (3) (%)
0.5 0
0.5 0
0.5 0
0.5 0.5
5 5
15 15
10 30
10 40
10 44.75
10 44.75
Med. Chem. Commun., 2014, 5, 904–914 | 907
Table 5 Local antiandrogenic activity of 4-related compounds 5, 8 and 9 in hamster ﬂank organ test
Compound Flank organ inhibitiona (%)
Cortexolone-21-propionate (5) 29
Cortexolone-17a,21-dipropionate (8) 57
9,11-Dehydrocortexolone-17a-butyrate (9)12 85
a Ability of the tested steroids (400 mg) to inhibit the enlargement of the hamster's organ ank produced by the administration of 4 mg of
testosterone propionate.
Fig. 3 Three-dimensional plots of the most populated conformations
of compounds 1 and 2.
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View Article OnlineCompound 7 shows a rigid structure and the only degree of
conformational freedom is the inversion of ring C. Rings A and
B could not be inverted because of the presence of the cyclo-
propane ring and the double bond, respectively. Nevertheless,
the C ring inversion gave conformations with a relative energy of
about 13 kcal mol1, giving no contribution to the overall
population. So, only two geometries, 7A and 7Ab, are populated
(Fig. 5). Conformation A of compound 7 presents the following
contacts: H-11b/CH3-18 (2.24 A˚), H-11b/CH3-19 (2.29 A˚), H-8/
CH3-19 (2.76 A˚), and H-9/CHa-cPr (2.66 A˚).
On the basis of crystallographic studies15 performed on
dihydrotestosterone (2) complexed with the ligand-binding
domain of the wild-type androgen receptor, both the carbonyl
oxygen atom bonded at C3 and the hydroxyl group at C17 of this
molecule actively contribute to the stabilization of the obtained
complex. The A ring conformation inuences the orientation of
the carbonyl group that deeply aﬀects the binding of the entire
molecule.
A docking study performed on 7,16 into the homology model
for the glucocorticoid receptor ligand binding domain, revealed
that in the active site it assumes conformation A.
The superimposition of the heavy atoms of the tetracyclic
system of the preferred conformations of compounds 3, 4 and
7–9 (Fig. 6) gave evidence that the presence of the hydroxyl
group or the ester chain, bonded to C21 in compounds 3, 4, 8
and 9, does not aﬀect the orientation of the substituent at C17.
Compounds 3, 4, 8 and 9 show a very good overlay, also
concerning the O3 atoms that are perfectly coincident, in spite
of the presence in 9 of a double bond on ring C. Conversely, the
overlay shows that in 7 the O3 atom is diﬀerently oriented and
diverges with the distance d(O–O)z 1.0 A˚.908 | Med. Chem. Commun., 2014, 5, 904–914NMR data
Complete 1H and 13C NMR signal assignments (Tables 7–9) of
the spectra of compounds 3, 4 and 7–9 were achieved using a
combination of 1D and 2D (COSY, HSQC and NOESY) experi-
ments recorded in CDCl3 at 298 K. In general, starting from
characteristic H-4, H-7 or H-11 olenic protons it was possible
to assign the resonances of all the other protons of the studied
steroids on the basis of their 2D spectra. First of all, H-8 was
assigned through COSY correlations from H-4 of compounds 3,
4, 8 and 9 or from H-7 of compound 7. Then, it was possible to
discriminate between H-9 and H-14 (showing two very clear and
distinctive HSQC cross-peaks accounting for C–H protons) on
the basis of H-9/H-11 coupling, with H-11b being assigned on
the basis of its NOESY cross-peak with 19-CH3 (previously
distinguished from 18-CH3 that showed a NOESY correlation
with the characteristic 21-protons). Also, H-1, and consequently
H-2, resonances were assigned through the NOESY cross-peak
of H-1b and 19-CH3. Finally, analysis of the 18- and 19-CH3
NOESY cross-peak network was especially useful for the
assignment of the a- or b-conguration of geminal protons (see
Table 7) of all the studied compounds. Even if some protons in
the 1H NMR spectra resonated as complex multiplets (see Table
7), many signals were well resolved and their coupling could be
measured. The obtained values are reported in Table 9 in
comparison with the calculated constants of compounds 3, 4
and 7–9. For each populated conformer the 1H vicinal coupling
constants were calculated with the electronegativity-modied
Karplus relationship17 and were weight-averaged on the basis of
the population percentages. The experimental and the calcu-
lated values resulted in close agreement. The following nuclear
Overhauser eﬀect (nOe) contacts were observed in the NOESY
spectra of the studied compounds. Compound 3: CH3-19/H-1b,
H-2b, H-6b, H-11b and H-8; CH3-18/H-11b, H-12b, H-15b, H-16b,
H-21b and H-8; H-21a/H-12b and H-16b; H-21b/H-16 b; and H-
7a/H-9 and H-14. Compounds 4 and 8: CH3-19/H-1b, H-2b, H-
6b, H-11b and H-8; CH3-18/H-11b, H-12b, H-15b, H-16b, H-21a
and H-8; H-21b/H-12b and H-16b; H-21a/H-16b; H-8/H-15b; and
H-7a/H-9 and H-14. Compound 9: CH3-19/H-1b, H-2b, H-6b,
H-11 (3.80 A˚ calcd) and H-8; CH3-18/H-11 (4.00 A˚ calcd), H-12b,
H-15b, H-16b, H-21a andH-8; H-21b/H-12b and H-16b; H-21a/H-
16b; H-8/H-15b; and H-7a/H-9 and H-14. Compound 7: CH3-19/
H-1, H-11b and H-8; CH3-18/H-11b, H-12b, H-15b, H-16b, CH3-
21 and H-8; CH3-21/H-12b and H-16b; H-8/H-15b; and H-9/
CHa-cPr.
These nOe data, such as the experimental values of the 1H
vicinal coupling constants, supported the calculated preferredThis journal is © The Royal Society of Chemistry 2014
Table 6 Geometrical features, relative energies, and equilibrium percentages of the selected conformations of compounds 1–4 and 7–9
Erel (kcal mol
1) % sA
a () sB
b () sC
c () s1
d () s10
e () s2
f () s3
g ()
Ring puckering coordinates
A ring B ring C ring D ring
Q f2 q Q f2 q Q f2 q q2 f2
1A 0.00 59.8 54 54 54 172 0.44 16 54 0.54 167 7 0.54 272 6 0.46 187
1Ab 0.27 37.7 54 54 54 64 0.44 16 54 0.54 167 7 0.57 271 6 0.46 187
1B 1.88 2.5 55 55 54 172 0.44 203 125 0.58 347 5 0.58 294 5 0.46 187
1C 6.05 0.0 48 51 54 172 0.45 347 54 0.72 261 84 0.59 335 5 0.47 188
1D 11.13 0.0 54 53 45 174 0.45 12 55 0.56 12 55 0.73 324 79 0.49 193
2A 0.00 62.8 51 54 54 173 — — — 0.54 285 10 0.57 320 4 0.57 275 5 0.47 188
2Ab 0.31 36.9 51 54 54 64 — — — 0.54 285 10 0.58 319 4 0.57 275 5 0.46 187
2B 3.15 0.3 28 55 54 173 — — — 0.77 265 85 0.56 210 4 0.57 276 5 0.46 188
2C 11.83 0.0 45 42 54 173 — — — 0.56 270 19 0.71 274 77 0.60 344 5 0.47 188
2D 11.50 0.0 49 55 45 174 — — — 0.54 278 12 0.59 216 5 0.73 215 78 0.50 193
3A 0.63 24.8 54 54 54 146 175 45 — 0.44 17 54 0.54 165 6 0.57 270 4 0.48 187
3Ab 0.00 71.7 54 54 54 24 169 159 — 0.44 17 54 0.54 169 6 0.57 271 5 0.48 188
3B 2.58 0.9 55 55 55 147 175 44 — 0.44 203 125 0.58 350 5 0.58 302 3 0.48 188
3Bb 1.96 2.6 55 55 54 24 169 158 — 0.44 203 125 0.58 349 5 0.58 299 4 0.48 188
3Cb 6.14 0.0 48 51 54 24 169 158 — 0.45 347 54 0.72 261 84 0.59 339 5 0.48 189
3Db 10.55 0.0 54 53 45 25 169 156 — 0.44 11 54 0.56 182 13 0.74 324 78 0.51 193
4A 0.00 66.0 54 54 55 156 163 65 — 0.44 17 54 0.54 163 6 0.57 271 3 0.47 190
4Ab 0.46 30.3 54 54 54 13 172 75 — 0.44 17 54 0.54 166 7 0.57 271 5 0.46 188
4B 1.93 2.6 55 54 55 156 163 65 — 0.44 202 125 0.58 345 5 0.58 298 3 0.47 190
4Bb 2.44 1.1 55 55 54 13 172 75 — 0.44 203 125 0.58 352 5 0.58 301 4 0.46 188
4C 6.20 0.0 49 51 55 156 164 65 — 0.45 348 53 0.72 261 84 0.59 353 4 0.48 192
4D 10.59 0.0 54 53 45 157 168 64 — 0.44 13 55 0.56 183 12 0.73 325 78 0.49 199
8A 1.29 9.8 54 54 54 155 150 65 95 0.44 17 54 0.54 166 6 0.57 268 4 0.46 190
8Ab 0.00 85.8 54 54 53 11 179 75 77 0.44 16 54 0.54 165 6 0.57 278 5 0.46 185
8B 3.17 0.4 55 55 55 156 149 66 96 0.44 203 125 0.58 353 5 0.58 312 3 0.47 191
8Bb 1.81 4.0 55 54 53 11 179 75 77 0.44 202 125 0.58 346 5 0.58 301 4 0.47 185
8Cb 6.10 0.00 48 51 54 11 179 75 77 0.45 347 54 0.72 261 84 0.59 344 5 0.47 187
8Db 10.25 0.00 54 53 43 12 179 74 77 0.46 22 49 0.56 183 13 0.73 323 78 0.49 192
9A 0.00 55.0 55 56 16 154 162 66 — 0.44 15 54 0.50 117 12 0.51 266 52 0.45 187
9Ab 0.25 36.0 55 56 15 13 172 76 — 0.44 14 54 0.50 116 12 0.51 267 52 0.45 183
9B 1.34 5.7 56 54 16 156 163 65 — 0.45 203 125 0.55 17 10 0.51 267 51 0.45 184
9Bb 1.68 3.2 56 54 16 13 172 76 — 0.45 203 125 0.55 20 10 0.51 267 51 0.44 183
9C 3.77 0.1 50 57 14 157 162 76 — 0.46 348 54 0.70 264 89 0.50 272 49 0.45 186
7A 0.00 82.0 6 1 54 156 — 67 — 0.30 301 81 0.49 259 51 0.58 316 3 0.47 191
7Ab 0.90 18.0 6 1 54 10 — 76 — 0.30 301 81 0.49 259 51 0.59 314 4 0.46 188
a sA: C10–C1–C2–C3.
b sB: C5–C6–C7–C8.
c sC: C9–C11–C12–C13.
d s1: C16–C17–O–H for 1 and 2, C16–C17–C20–C21 for 3, 4, 7–9.
e s10: C17–C20–
C21–O. f s2: C16–C17–O–H for 3, C16–C17–O–C170 for 4, 7–9.
g s3: C20–C21–O–C22.
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View Article Onlineconformations. In particular, almost all these contacts correspond
to distances of <3 A˚ as measured on the computed (Fig. 4 and 5)
most populated conformations of compounds 3, 4 and 7–9.
Discussion
Cortexolone-17a-propionate (4) is a steroid endowed with a
strong local antiandrogenic activity but it is devoid of systemic
antiandrogenic activity and it does not aﬀect the hypersecretion
of gonadotropins. Cortexolone-17a-propionate (4) does not
inhibit the conversion of testosterone (1) to DHT (2) in recon-
structed human epidermis, thus resulting in being devoid of
activity on the 5a-reductase. Nevertheless, compound 4
competes with the androgens at the androgen receptor level,
and thus its strong antiandrogenic activity is attributable to this
mechanism of action. As a consequence it is under investigation
in the management of acne and alopecia.This journal is © The Royal Society of Chemistry 2014In the present work a conformational comparison of 4 with
testosterone (1), active testosterone metabolite DHT (2) and
antiandrogen cyproterone acetate (7) (similar to 4 for the action
mechanism direct on the androgen receptor) was carried out by
means of theoretical calculations, supported by their complete
high-eld NMR characterization. In addition, the comparison
was extended to the related compounds cortexolone (3), devoid
of activity, cortexolone-17a,21-dipropionate (8), less active, and
D9-butyrate 9, active both topically and systemically.
The conformational characterization showed that all
compounds are similar (see Fig. 6), minor diﬀerences being
observed: cyproterone acetate (7) has the 3-carbonyl group
diﬀerently oriented and the presence of the 9,11-double bond
hampers the C ring inversion in compound 9. However the
3-carbonyl group orientation (7 vs. 4, Table 1) and the
conformation of the C ring (9 vs. 4, Tables 1 and 5) do not
inuence the extent of the local antiandrogenic activity of theMed. Chem. Commun., 2014, 5, 904–914 | 909
Fig. 4 Three-dimensional plots of the most signiﬁcant conformations
of compounds 3, 4, 8 and 9.
Fig. 5 Three-dimensional plots of the most signiﬁcant conformations
of compound 7.
Fig. 6 Overlap of preferred conformations of compounds 3 (green
shading), 4 (red shading), 8 (yellow shading), 9 (pink shading), and 7
(brown shading) obtained through rms ﬁtting of the heavy atoms of the
tetracyclic system.
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View Article Onlinetested compounds. By contrast, the presence of the 17a-ester
group, which was always oriented in the same way from the
conformational study, seems to be mandatory for a good910 | Med. Chem. Commun., 2014, 5, 904–914inhibitory activity (3 vs. 4, Table 1). In conclusion, the cortex-
olone series compounds 3–5 and 8, cyproterone acetate (7),
and D9-17a-butyrate 9 share the same skeleton conformation
but show diﬀerent antiandrogenic activities due to the pres-
ence of an acyl chain linked to the 17a-hydroxyl functionality.
The same skeleton conformation of the examined compounds
is consistent with the capability of each of them to interact,
even with diﬀerent outcomes, with the androgen receptors.
Furthermore, the absence of systemic activity of 4 could be
explained by its metabolic fate, i.e. the esterases-catalyzed
hydrolysis of the acyl chain, aer the rapid migration from the
17- to the 21-position.
Experimental
Materials and methods
All the cortexolone derivatives were from an internal source.
Others steroids, Sephadex LH-20 and all reagents and solvents
were purchased from Sigma Aldrich, Milan (Italy); Extrelut® NT
columns were obtained from Merck.
Biological tests
Animals. Female Syrian golden hamsters and Wistar Han
rats of both sexes (Charles River, Italy) were used in the exper-
iments. The experiments were approved by the local Institu-
tional Ethical Committee, and were conducted in agreement
with the EEC Directive 86/609 and with the Italian Legislative
Decree 116/27.01.1992 concerning the protection of animals
used for experimental purpose or other scientic scope.
Hamster ank organ test. Female Syrian golden hamsters,
60–90 g body weight, were treated for 21 consecutive days with
cortexolone-17a-propionate (4) and related compounds 5, 8, 9This journal is © The Royal Society of Chemistry 2014
Table 7 1H NMR chemical shifts (ppm) of compounds 3, 4, and 7–9
1H 3 4 7 8 9
1 1.70
1a 1.66 1.71 — 1.70 2.06–2.17
1b 2.00 2.02 — 2.02 2.06–2.17
2 2.00
2a 2.32 2.32 — 2.34 2.43–2.50
2b 2.39 2.41 — 2.40 2.43–2.50
CHa (cPr) — — 0.86 — —
CHb (cPr) — — 1.26 — —
4 5.70 5.72 6.16 5.72 5.74
6a 2.26 2.27 — 2.27 2.35
6b 2.38 2.38 — 2.38 2.56
7 — — 6.20 — —
7a 1.08 1.10 — 1.08 1.16
7b 1.85 1.85 — 1.84 2.01
8 1.59 1.60 2.31 1.62 2.22
9 0.95 1.00 1.45 0.99 —
11 — — — — 5.52
11a 1.62 1.65 1.94 1.65 —
11b 1.38 1.40 1.55 1.45 —
12a 1.72 1.89 2.03 1.88 2.75
12b 1.40 1.54 1.61 1.74 1.76
14 1.70 1.67 1.96 1.67 1.85
15a 1.80 1.76 1.89 1.72 1.94
15b 1.37 1.35 1.44 1.34 1.45
16a 1.57 1.85 1.82 1.84 1.97
16b 2.66 2.81 2.98 2.82 2.80
17 (OCOCH2) — 2.34 — 2.35 2.28
17 (OCOCH2CH3) — 1.12 — 1.13 —
17 (OCOCH2CH2) — — — — 1.62
17 (OCOCH2CH2CH3) — — — — 0.93
17 (OCOCH3) — — 2.09 — —
17 OH 2.45 — — — —
18 (CH3) 0.68 0.66 0.71 0.74 0.61
19 (CH3) 1.16 1.17 1.21 1.16 1.32
21 (CH3) — — 2.04 — —
21a 4.28 4.21 — 4.59 4.24
21b 4.64 4.26 — 4.87 4.28
21 (OCOCH2) — — — 2.45 —
21 (OCOCH2CH3) — — — 1.15 —
21 OH 3.09 3.03 — — 3.04
Table 8 13C NMR chemical shifts (ppm) of compounds 3, 4, and 7–9
13C 3 4 7 8 9
1 35.68 35.70 26.07 35.67 33.83
2 33.87 33.91 25.22 33.92 34.22
CH2 (cPr) — — 12.29 — —
3 199.58 199.26 197.94 199.40 199.05
(199.04)
4 123.94 124.07 120.51 123.98 124.17
5 170.93 170.33 155.22 170.61 169.01
6 32.73 32.65 130.23 32.69 32.70
7 31.98 31.91 136.51 31.91 32.13
8 35.59 35.57 38.33 35.57 37.48
9 53.28 53.16 47.70 53.14 144.20
10 38.54 38.53 38.70 38.54 40.98
11 20.52 20.50 20.78 20.57 118.25
12 30.08 30.46 31.02 30.24 32.35
13 48.57 47.72 47.24 47.79 46.28
14 50.28 50.93 48.77 50.94 48.16
15 23.70 23.89 23.23 23.77 24.65
16 34.52 30.77 30.30 30.78 30.52
17 89.00 93.77 96.18 94.86 93.33
17 (OCO) — 174.05 170.55 174.20 173.24
(174.02)
17 (OCOCH3) — — 21.17 — —
17 (OCOCH2) — 27.77 — 27.10 36.24
(27.90)
17 (OCOCH2CH3) — 8.85 — 8.97 —
(8.90)
17 (OCOCH2CH2) — — — — 18.31
17 (OCOCH2 CH2CH3) — — — — 13.57
18 14.99 14.29 14.19 13.75 14.31
19 17.36 17.39 22.83 17.35 26.20
20 212.33 206.21 203.61 199.40 206.22
(199.04)
21 67.42 66.93 26.43 66.88 66.91
21 (OCO) — — — 174.20 —
(174.02)
21 (OCOCH2) — — — 27.10 —
(27.90)
21 (OCOCH2CH3) — — — 8.97 —
(8.90)
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View Article Onlineapplied directly onto the right ank organ at a daily dose
ranging from 100 to 400 mg. The products were dissolved in
0.05 mL acetone solution containing 4 mg of TP. Parent cor-
texolone (3), progesterone, cyproterone acetate (7) and nas-
teride (6) were also tested. Control groups of animals treated
with TP alone have also been included. The antiandrogenic
activity of the compounds was assessed by their ability to
reduce the enlargement of the ank organs induced by TP
alone.
Systemic antiandrogenic and glucocorticoid activity. Male
castrated Wistar rats, 45–50 g body weight, were subcutane-
ously injected, for seven consecutive days, with cortexolone-
17a-propionate (4) or with 9,11-dehydrocortexolone-17a-
butyrate (9) (0.2–1 and 5 mg), and with 40 mg of TP. Parent
cortexolone (3) was also tested at a daily dose of 5 mg. Control
groups of untreated or treated animals with TP alone were
also included. The antiandrogenic activity of 4 and 9 was
evaluated by their ability to antagonize the androgenic eﬀectThis journal is © The Royal Society of Chemistry 2014induced by TP on the target androgenic organs: ventral
prostate, seminal vesicles, and preputial glands. The weight
reduction of adrenals and thymus was assumed as the
glucocorticoid activity index.
Antigonadotropic activity.Wistar rats of both sexes, 50–60 g
body weight, were employed. The males were castrated and, on
the following day, they were surgically joined with intact
females in latero-lateral parabiosis. In this model the castra-
tion induces a prompt increase of male gonadotropins which,
in turn, reach the intact partner females and stimulate the
ovarian growth. Starting on the day aer parabiosis, each male
was subcutaneously injected with cortexolone-17a-propionate
(4) or with 9,11-dehydrocortexolone-17a-butyrate (9) at doses
of 1 and 5 mg. Progesterone was assumed as the standard
control and was administered, using the same procedure, at
doses of 0.5 and 2 mg. The treatment lasted for eight consec-
utive days, aer which the couples were autopsied. The ovaries
were isolated and weighed. The inhibitory activity against
gonadotropin hypersecretion, induced by castration in theMed. Chem. Commun., 2014, 5, 904–914 | 911
Table 9 1H NMR coupling constants (Hz) of compounds 3, 4, and 7–9
J
3 3 4 4 7 7 8 8 9 9
Exp Calc Exp Calc Exp Calc Exp Calc Exp Calc
1a,1b 13.4 13.4 — 13.4 n.d.
1a,2a 4.5 4.0 5.0 3.9 — n.d. 3.9 n.d. 3.9
1a,2b n.d 13.5 n.d 13.5 — n.d. 13.6 n.d. 13.6
1b,2a 3.2 2.9 3.3 2.9 — 2.7 2.9 n.d. 2.9
1b,2b 5.0 3.4 5.0 3.4 — 4.8 3.4 n.d. 3.5
2b,2a 16.7 16.7 — n.d. n.d.
1,2 — — 7.9 10.5 — —
1,CHa (cPr) — — 6.4 9.5 — —
1,CHb (cPr) — — 7.9 10.3 — —
2,CHa (cPr) — — 4.5 8.2 — —
2,CHb (cPr) — — 8.9 10.4 — —
CHa,CHb(cPr) — — 4.8 — —
6a,6b 14.6 14.6 — 14.5 14.4
6a,7a 4.3 3.7 4.2 3.7 — 4.0 3.7 3.9 3.3
6a,7b 2.4 2.9 2.4 2.9 — 2.4 2.9 2.6 3.1
6b,4 n.d. n.d — n.d. 1.9
6b,7a 12.0 13.2 11.5 13.3 — 12.0 13.3 14.4 13.4
6b,7b n.d. 3.8 5.0 3.8 — n.d. 3.8 4.8 3.5
7a,7b 13.0 13.7 — 14.0 12.4
7a,8 12.0 12.3 12.5 12.3 — 12.0 12.4 12.5 12.4
7b,8 n.d. 3.4 3.3 3.2 — 3.3 3.2 4.7 3.2
7,8 — — 2.0 1.0 — —
8,9 10.8 12.1 11.0 12.3 9.8 12.9 10.8 12.9 —
8,14 n.d. 12.1 11.0 12.3 10.0 10.8 10.8
8,12a — — — — 2.9
8,12b — — — — 2.0
11,8 — — — — 2.0
11,12a — — — — 2.9 2.0
11,12b — — — — 5.9 6.4
9,11a 4.2 3.4 4.0 3.0 4.1 —
9,11b 11.8 12.3 12.5 12.8 13.0 —
11a,12a n.d. 3.8 4.3 3.8 n.d. 4.3 4.0 —
11a,12b n.d. 2.8 2.9 2.9 2.7 n.d. 2.6 —
11b,12a n.d. 13.2 13.0 13.2 12.8 13.2 13.1 —
11b,12b n.d. 4.1 4.2 4.0 4.0 4.2 4.4 —
11a,11b n.d. 13.4 12.8 13.2 —
12a,12b n.d. 13.0 12.6 13.0 17.0
14,15a n.d. 5.8 7.0 5.4 n.d. n.d. 7.7 6.1
14,15b n.d. 11.6 11.8 11.8 11.0 11.3 11.0 11.3
15a,16a 9.4 11.0 9.4 11.8 9.2 n.d. 12.0 9.4 11.0
15a,16b 3.0 2.3 2.6 2.1 2.4 2.5 2.6 3.0 2.7
15a,15b n.d. 11.8 11.6 11.3 17.0
15b,16a 6.2 5.4 6.5 5.7 6.0 6.5 4.7 5.0 4.9
15b,16b 11.5 12.0 11.8 11.8 10.2 11.3 12.0 12.5 12.0
16a,16b 14.8 16.0 15.7 15.7 15.2
21a,21b 19.8 18.2 — 16.5 18.3
21a,OH 4.5 4.9 — — 4.9
21b,OH 4.5 4.9 — — 4.8
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View Article Onlinemales, was evaluated by the ability of 4 and 9 to antagonise the
ovarian weight increase.
Metabolism
Metabolism in rat and human plasma. Samples of rat
plasma were incubated at 37.8 C with cortexolone-17a-
propionate (4) (0.4 mg mL1) for 8 h in the presence or
absence of 50 mg of enzymatic inhibitor dichlorvos. Deter-
mination of 4, free cortexolone (3), and cortexolone-21-
propionate (5) were carried out at 5, 15, and 30 min and 1, 2,
4, and 8 h incubation periods by HPLC. Samples of human912 | Med. Chem. Commun., 2014, 5, 904–914plasma were incubated with cortexolone-17a-propionate (4)
(0.4 mg mL1) at 37.8 C for 6 h. Determination of 4, free
cortexolone (3), and cortexolone-21-propionate (5) was per-
formed at 30 min and 1, 2, 4, and 6 h incubation periods by
HPLC.
Metabolism in rat skin homogenate. Dorsal skin samples of
male rats (Harlan Laboratories, Italy) were homogenised and
incubated at 36.5 C with cortexolone-17a-propionate (4)
(0.4 mg mL1). Determination of 4, free cortexolone (3) and
cortexolone-21-propionate (5) were done at 30 min and at 1, 4, 8,
16, and 24 h incubation periods by HPLC.This journal is © The Royal Society of Chemistry 2014
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View Article OnlineDetermination of 3, 4 and 5 by LC-MS and HPLC analyses
Instruments. HPLC analyses were performed using a Merck-
Hitachi L-6200. An LiChrospher 100 RP-18 (Merck) column
(244 mm  4 mm i.d., 5 mm) was employed; acetonitrile–water
(65/35 v/v) was used at ow rate of 1 mL min1, at room
temperature. The detector wavelength was set at 240 nm. Mass
spectrometry analysis was carried out using an LCQDECA ion
trap mass analyser (TermoQuest, San Jose, USA) with an elec-
trospray ionization ESI interface in negative ion mode. The
HPLC apparatus comprised a Thermo Finningan Mat P 4000
series pump and vacuum degasser. The method was adapted
from the method developed for HPLC-UV assay (same column,
ow rate and mobile phase). Data were processed using Xcali-
bur soware 1.1. The optimized parameters were as follows:
source voltage 5.00 kV; sheath gas ow rate 50 mL min1;
capillary voltage 15 V; capillary temp. 250 C.
Preparation of samples. The samples obtained from incu-
bations were loaded onto an Extrelut® NT column; the steroids
were eluted using ethyl acetate (3  5 mL). The combined
organic extracts were evaporated under a stream of nitrogen at
50 C. The dried extracts were dissolved in cyclohexane–ethyl
acetate (7 : 3, 0.5 mL) and puried by gel chromatography on a
Sephadex LH-20 column using cyclohexane–ethyl acetate (7 : 3)
as the eluant; the rst eluted 15 mL were collected and taken to
dryness under a stream of nitrogen.
LC-MS analysis. The samples were dissolved in acetonitrile
(1 mL) and an amount (15 ml) was analyzed by LC-MS. The
observed peaks were identied, by comparison with standard
samples, as cortexolone (3), cortexolone-17a-propionate (4) and
cortexolone-21-propionate (5). The three standard solutions
(1 mg mL1) were previously injected (5 ml); the retention time
and the observed m/z values are reported in Table 10.
In order to quantify the percentage of each compound the
samples were analyzed by HPLC.
HPLC analysis. The quantitative analysis was performed by
HPLC, using the same samples analyzed by LC-MS, the results
being expressed as area%: the three standard solutions and the
samples of plasma and of skin homogenates were analyzed in
duplicate.
Statistical analyses. The data collected in the animal studies
have been statistically analyzed for signicant diﬀerences
according to Student's test. A P value of <0.05 was considered
statistically signicant.Computational methods
All calculations were carried out using the Gaussian0318
program package. The conformational space of compounds 1–4Table 10 Retention time and observed m/z values of standard
samples 3, 4 and 5
Std M RT (min) m/z
3 346.21 3.48–3.89 345.0 [M  1], 691.3 [2M  1]
4 402.24 5.38–5.67 803.1 [2M  1]
5 402.24 7.05–7.59 803.2 [2M  1]
This journal is © The Royal Society of Chemistry 2014and 7–9 was explored through optimization of all the possible
starting geometries which were optimized within the DFT
approach at the B3LYP level with the 6-31G(d) basis set. All the
degrees of conformational freedom were considered, in partic-
ular the possible existence of diﬀerent conformations at the A,
B, and C hexacyclic rings as well as the orientation of the groups
bonded at C17. Several conformations were located for each
compound and the corresponding percentage contributions to
the overall population were determined using the Boltzmann
equation. The geometry of the rings A–C is described through
two kinds of descriptors, i.e., a signicant torsion angle for each
ring, sA, sB, sC, and the ring-puckering coordinates determined
according to Cremer and Pople.19 Vibrational frequencies were
computed at the same level as above in order to verify that the
optimized structures were minima. The 1H vicinal coupling
constants were calculated with the electronegativity-modied
Karplus relationship17 and were weight-averaged on the basis of
the population percentages.NMR spectroscopy
All NMR spectra were recorded at 298 K using a Bruker AVANCE-
500 spectrometer operating at 500.13 and 125.76 MHz for 1H
and 13C, respectively, using a 5 mm single-pulsed eld gradient
(z-PFG) broadband reverse probe. Chemical shis are reported
on the d (ppm) scale and are relative to chloroform signals (7.24
for 1H and 77.0 ppm, central line, for 13C spectra respectively).
Compounds 3, 4 and 7–9 (about 10 mg) were dissolved in CDCl3
(0.5 mL) under N2, and their assignments were given by a
combination of 1D and 2D COSY, HSQC and NOESY experi-
ments, using standard Bruker pulse programs. z-PFGs were
used to obtain 1H–1H COSY and HSQC spectra. The pulse
widths were 7.50 ms (90) and 14.5 ms (90) for 1H and 13C
respectively. Typically, 32 768 data points were collected for
one-dimensional spectra. Spectral widths were 11.45 ppm
(5733 Hz) for 1H NMR (digital resolution: 0.17 Hz per point) and
259.84 ppm (32 680 Hz) for 13C NMR (digital resolution: 1.0 Hz
per point). 2D experiments parameters were as follows. For
1H–1H correlations: relaxation delay 2.0 s, 1024  1024 data
point matrices (512 experiments to 1024 zero lling in F1, 1024
in F2), 2 or 16 transients in each experiment for COSY and
NOESY respectively, spectral width 6.0 ppm (3004.8 Hz). The
NOESY spectra were generated with a mixing time of 1.0 s and
acquired in the TPPI mode. There were no signicant diﬀer-
ences in the results obtained at diﬀerent mixing times (0.5–
1.5 s). For 13C–1H correlations (HSQC): relaxation delay 2.5 s,
1024  1024 data point matrices (512 experiments to 1024 zero
lling in F1, 1024 in F2), 2 transients in each experiment,
spectral width 6.0 ppm (3004.8 Hz) in the proton domain and
180.0 ppm (22 638.6 Hz) in the carbon domain. All 2D spectra
were processed using the Bruker soware package.Acknowledgements
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